The pharmaceutical industry is currently navigating a complex landscape as recent tariff decisions by President Trump provide both temporary relief and looming challenges. While some pharmaceutical stocks saw significant gains after being exempted from new tariffs, experts warn that this reprieve may be short-lived as further tariffs are discussed. Amidst a chaotic rollout of tariffs, drugmakers are scrambling to understand the potential impacts on the global supply chain. Experts have noted that while Indian pharmaceutical companies have benefited from these exemptions, the future remains uncertain as the possibility of sector-specific duties looms. Investors are advised to remain vigilant as tariff policies could drastically affect pricing and availability of drugs globally.